Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Showing posts with label Middle Cerebral Artery Occlusion. Show all posts
Showing posts with label Middle Cerebral Artery Occlusion. Show all posts

Sunday, June 23, 2024

Comparing Outcomes of Thrombectomy Versus Intravenous Thrombolysis Based on Middle Cerebral Artery M2 Occlusion Features

 So everything here was a failure, nobody got to 100% recovery! Damn it all, that is the only goal in stroke that survivors want! GET THERE!

Comparing Outcomes of Thrombectomy Versus Intravenous Thrombolysis Based on Middle Cerebral Artery M2 Occlusion Features

Originally publishedhttps://doi.org/10.1161/STROKEAHA.123.044986Stroke. 2024;55:1592–1600

Abstract

BACKGROUND:

Current evidence provides limited support for the superiority of endovascular thrombectomy (EVT) in patients with M2 segment middle cerebral artery occlusion. We aim to investigate whether imaging features of M2 segment occlusion impact the effectiveness of EVT.

METHODS:

We conducted a retrospective cohort study from January 2017 to January 2022, drawing data from the CASE II registry (Computer-Based Online Database of Acute Stroke Patients for Stroke Management Quality Evaluation), which specifically documented patients with acute ischemic stroke presenting with M2 segment occlusion undergoing reperfusion therapy. Patients were stratified into the intravenous thrombolysis (IVT) group (IVT alone) and EVT group (IVT plus EVT or EVT alone). The primary outcome was a modified Rankin Scale score 0 to 2 at 90 days. Secondary outcomes included additional thresholds and distribution of modified Rankin Scale scores, 24-hour recanalization, early neurological deterioration, and relevant complications during hospitalization. Safety outcomes encompassed intracranial hemorrhagic events at 24 hours and mortality at 90 days. Binary logistic regression analyses with propensity score matching were used. Subgroup analyses were performed based on the anatomic site of occlusion, including right versus left, proximal versus distal, dominant/co-dominant versus nondominant, single versus double/triple branch(es), and anterior versus central/posterior branch.

RESULTS:

Among 734 patients (43.3% were females; median age, 73 years) with M2 segment occlusion, 342 (46.6%) were in the EVT group. Propensity score matching analysis revealed no statistical difference in the primary outcome (odds ratio, 0.860 [95% CI, 0.611–1.209]; P=0.385) between the EVT group and IVT group. However, EVT was associated with a higher incidence of subarachnoid hemorrhage (odds ratio, 6.655 [95% CI, 1.487–29.788]; P=0.004) and pneumonia (odds ratio, 2.015 [95% CI, 1.364–2.977]; P<0.001). Subgroup analyses indicated that patients in the IVT group achieved better outcomes(NOT RECOVERY!) when presenting with right, distal, or nondominant branch occlusion (Pall interaction<0.05).

CONCLUSIONS:

Our study showed similar efficiency of EVT versus IVT alone in acute M2 segment middle cerebral artery occlusion. This suggested that only specific patient subpopulations might have a potentially higher benefit of EVT over IVT alone.

REGISTRATION:

URL: https://clinicaltrials.gov; Unique identifier: NCT04487340.

Five randomized clinical trials issued in 2015 have confirmed the superiority of endovascular thrombectomy (EVT) over medical management in patients of acute ischemic stroke (AIS) with anterior large vessel occlusion.1–5 However, patients with AIS enrolled in these trials mainly suffered from proximal large vessel occlusion, including internal carotid artery and M1 segment middle cerebral artery (MCA). In a meta-analysis of individual patient data from the above trials, only 95 patients were finally identified as M2 segment MCA occlusion,6 resulting in limited evidence for the efficacy of EVT in this subgroup.7

In previous post hoc studies, EVT was considered an effective measure that could improve(NOT GOOD ENOUGH!) clinical outcomes in acute M2 occlusion, when compared with the control group who received medical management, that is, intravenous thrombolysis (IVT) or antiplatelet therapy if IVT is not applicable.8–10 However, patients with AIS with M2 occlusion who received EVT achieved similar functional outcomes when compared with those with IVT alone,11 which might be due to a potentially beneficial treatment effect of IVT on more distal clot locations.12

Some M2 segment is the dominant artery supplying blood to a large portion of the MCA territory, presenting as severe neurological impairment and sizable infarction after occlusion, but is as easily accessible for EVT as the M1 segment.13–15 Hence, patients with the clot situated in the dominant M2 artery or in close proximity to the furcation are likely to experience similar benefits from EVT. We hypothesized that imaging features of M2 segment MCA occlusions might affect the efficacy and safety of EVT, either with or without IVT. In the current study, we sought to investigate whether certain anatomic characteristics of M2 segment occlusions such as location, size, anatomy, and number of vessels occluded could help select patients who would benefit more from EVT than IVT alone.

Saturday, January 20, 2024

Early Metabolic Alteration Predicts Outcome With Middle Cerebral Artery Occlusion Treated by Mechanical Thrombectomy

You're predicting failure to recover rather than doing the research survivors want! 100% RECOVERY! I'D HAVE YOU ALL FIRED!

Early Metabolic Alteration Predicts Outcome With Middle Cerebral Artery Occlusion Treated by Mechanical Thrombectomy

Originally publishedhttps://doi.org/10.1161/SVIN.123.000972Stroke: Vascular and Interventional Neurology. 2023;3:e000972

Abstract

Background

Predicting clinical outcome based on either the postprocedural recanalization score (modified treatment in cerebral infarction) or the initial National Institute of Health Stroke Scale (NIHSS) clinical score performed immediately after the acute phase remains controversial. The gold standard to predict clinical outcome is the NIHSS score with diffusion weighted imaging. However, magnetic resonance spectroscopy could provide useful metabolic informations. Our study aimed to determine early metabolic factors predictive of long‐term clinical outcome after acute ischemic stroke in patients with middle cerebral artery occlusion successfully treated by mechanical thrombectomy.

Methods

Patients with proximal middle cerebral artery occlusion, an NIHSS score greater than 6 and successfully treated by mechanical thrombectomy with or without intravenous therapy were included. All patients underwent within 24 hours after mechanical thrombectomy, brain magnetic resonance imaging examination with multivoxel proton‐phosphorus‐magnetic resonance spectroscopy. Functional disability at 90 days with reference to pre‐stroke activities was categorized using the modified Rankin scale. Metabolite ratios were measured and confronted to modified Rankin scale.

Results

A total of 49 patients were included with initial mean NIHSS of 15.19±5.48. Time delay between: onset‐thrombectomy was 6.77 hours±3.22, thrombectomy‐magnetic resonance imaging was 29.83 hours±15.01. Results in the lesion compared with the contralateral area show an increase of Lac/Cr (0.88 versus 0.21; P<10−10) and a decrease of PhosphoMonoEster/PhosphoDiEster (0.80 versus 0.83; P=0.00165). Lac/Cr in the lesion was significantly higher in the poor outcome group than in the favorable outcome group (1.03±0.41 and 0.75±0.42; P=0.01). Our model built with NIHSS+proton‐magnetic resonance spectroscopy compared with the gold standard model (NIHSS+diffusion weighted imaging) is better (85.29% versus 77.55%) to predict clinical outcome.

Conclusion

Our study shows that early Lac/Cr alteration visible 24 hours after stroke is a strong predictor of 90 days clinical outcome for middle cerebral artery occlusion patients successfully treated(It's not successful if you don't get to 100% recovery! Unless of course you abide by the tyranny of low expectations that your medical providers use!) by mechanical thrombectomy. Our NIHSS+proton‐magnetic resonance spectroscopy model is the first to predict patients’ long‐term functional outcome with an accuracy of 85.3%, superior to existing models including diffusion weighted imaging.

Graphic Abstract: